Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Central Hospital, Nancy, France
The goal of this retrospective observational study is to evaluate if lung distension disorders can be a predictive factor of bad response to vasodilator therapy in patients with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD).
The study will include all patients from the hospital, followed for PH associated with COPD under vasodilator therapy between 2015 and 2021.
It will evaluate patients' lung hyperinflation according to the RV/TLC ratio and their response to treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with COPD regardless of severity defined as a FEV1/FVC ratio less than 0.70 and the presence of a risk factor (smoke exposure with at least a 10 pack-year history, or professional exposition) diagnosed with PH according to ESC/ERS 2022 classification and in whom vasodilator therapy has been initiated
You may not be if
other known concomitant lung disease (interstitial lung disease, cystic lung disease, mucoviscidosis…)
thoracic pathology such as kyphoscoliosis
pleural effusion (unless part of pulmonary veno-occlusive disease)
a large tumor lung mass
EFR missing or uninterpretable because difficult to perform
initiation of calcium channel blockers
surgical treatment in chronic thrombo-embolic pulmonary hypertension
no follow-up evaluation (lost to follow-up or died before reassessment)
Clareo Health | Lung Hyperinflation and Response to Pulmonary Vasodilator Therapy
